AdapCS

AdapCS is a Swiss biotechnology company focused on developing next-generation cytokine therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary Adaptive Cytokine Selection (AdapCS) platform to engineer cytokines with improved selectivity and reduced toxicity compared to wild-type variants. Their lead programs focus on optimizing Interleukin-2 (IL-2) and Interleukin-15 (IL-15) to specifically target effector T cells and natural killer cells while avoiding the activation of regulatory T cells. By fine-tuning the interaction between cytokines and their receptors, AdapCS aims to provide potent anti-tumor immune responses with a superior safety profile. The company is a spin-off from the University of Zurich and is backed by leading European venture capital firms.